BIM
ITCI

Bogle Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bogle Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-161,458
Closed -$2.62M – 386
2017
Q1 		$2.62M Sell
161,458
-292,076
-64% -$4.23M 0.18% 139
2016
Q4 		$6.84M Buy
+453,534
New +$6.4M 0.47% 76

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Bogle Investment Management's ITCI Position: Q2 2017 in Review

Bogle Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2017, closing a stake of 161,458 shares — an estimated $2.62M sold.

Bogle Investment Management first reported a position in ITCI in Q4 2016 and held it in 2 quarters. The position peaked at $6.84M in Q4 2016. 100 funds tracked by Wall St. Rank hold ITCI as of Q2 2017.

  • Bogle Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2017 after selling out during the quarter.
  • Bogle Investment Management sold 161,458 Intra-Cellular Therapies Inc. shares in Q2 2017, an estimated $2.62M.
  • Bogle Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 2 quarters.
  • Bogle Investment Management's Intra-Cellular Therapies Inc. position peaked at $6.84M in Q4 2016.
  • 100 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2017.

Based on Bogle Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.